US Patent

US10653710 — Combination therapy for treating malignancies

Method of Use · Assigned to Celgene Corp · Expires 2036-10-18 · 10y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for treating hematological malignancies in patients with an IDH1 mutation using a combination of a specific inhibitor and a DNA demethylating agent.

USPTO Abstract

Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent.

Drugs covered by this patent

Tibsovo (IVOSIDENIB) · Servier

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3387`	—	Tibsovo

Patent Metadata

Patent number: US10653710
Jurisdiction: US
Classification: Method of Use
Expires: 2036-10-18
Drug substance claim: No
Drug product claim: No
Assignee: Celgene Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.